Gemcitabine plus infusional 5-fluorouracil and high dose leucovorin in advanced stage pancreatic cancer

Oztop İ., Alacacioglu A., ÜNEK İ. T., Tarhan O., Somali I., Cokmert S., ...Daha Fazla

JOURNAL OF BUON, cilt.15, sa.3, ss.462-469, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 3
  • Basım Tarihi: 2010
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.462-469
  • Anahtar Kelimeler: advanced stage, 5-fluorouracil, gemcitabine, pancreatic cancer
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: Advanced pancreatic cancer (APC) has a poor prognosis and chemotherapy remains the primary treatment modality. Gemcitabine (GEM) and 5-fluorouracil (5-FU) are the most active drugs in the treatment of pancreatic cancer This study evaluated the efficacy and tolerability of the combination of these agents in APC. Methods: Forty-four patients with APC were treated with GEM and infusional 5-FU with high dose leucovorin (LV5FU2) (GEMFUFOL regimen). Results: A total of 240 chemotherapy cycles were administered. The overall response rate was 27.2%, and all responses were partial. Furthermore, disease stabilization was observed in 12 patients (27.2%). Median survival time and one-year survival rate were 9 months and 36.4%, respectively The overall grade 3 or 4 adverse events were very low and mostly hematological. Conclusion: GEMFUFOL is still an active regimen for the treatment of APC and has an acceptable toxicity.